<DOC>
	<DOCNO>NCT02515032</DOCNO>
	<brief_summary>SF-C002 pilot study patient newly diagnose NSCLC suffer involuntary weight loss . The study 12 week , double-blinded , placebo control main objective study safety tolerability Nutrifriend Cachexia .</brief_summary>
	<brief_title>Pilot Study Safety Tolerability Nutrifriend Cachexia NSCLC Cachexia</brief_title>
	<detailed_description>This study 12-week , randomise , parallel group , placebo control , multi-centre study . The primary objective evaluate safety tolerability Nutrifriend Cachexia patient NSCLC . The secondary objective study evaluate effect body composition , muscle function , daily activity , inflammation , tumor growth , compliance , appetite Quality Life .</detailed_description>
	<mesh_term>Cachexia</mesh_term>
	<criteria>Firstline standard chemotherapy curative palliative treatment NSCLC Will start first cycle standard chemotherapy Eastern Cooperative Oncology Group ( ECOG ) performance status â‰¤2 Involuntary weight loss Another invasive malignancy last 2 year . Previous relapse NSCLC within 2 year randomisation Other cachectic disorder renal hepatic disorder</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>